SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
SEC Accession No. 0001193125-16-647686
Filing Date
2016-07-14
Accepted
2016-07-14 06:06:07
Documents
9
Effectiveness Date
2016-07-14

Document Format Files

Seq Description Document Type Size
1 DEFM14A d212696ddefm14a.htm DEFM14A 778310
2 GRAPHIC g212696g11y77.jpg GRAPHIC 26592
3 GRAPHIC g212696g16r08.jpg GRAPHIC 27424
4 GRAPHIC g212696g21j11.jpg GRAPHIC 24658
5 GRAPHIC g212696g50i50.jpg GRAPHIC 25468
6 GRAPHIC g212696g54i28.jpg GRAPHIC 27174
7 GRAPHIC g212696g56z83.jpg GRAPHIC 16586
8 GRAPHIC g212696g57f70.jpg GRAPHIC 22487
9 GRAPHIC g212696g91g40.jpg GRAPHIC 29412
  Complete submission text file 0001193125-16-647686.txt   1055460
Mailing Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 400 CAMBRIDGE MA 02142 617-871-9911
Eleven Biotherapeutics, Inc. (Filer) CIK: 0001485003 (see all company filings)

IRS No.: 252025616 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFM14A | Act: 34 | File No.: 001-36296 | Film No.: 161766488
SIC: 2834 Pharmaceutical Preparations